These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 27893461)

  • 1. Dual modulation of MCL-1 and mTOR determines the response to sunitinib.
    Elgendy M; Abdel-Aziz AK; Renne SL; Bornaghi V; Procopio G; Colecchia M; Kanesvaran R; Toh CK; Bossi D; Pallavicini I; Perez-Gracia JL; Lozano MD; Giandomenico V; Mercurio C; Lanfrancone L; Fazio N; Nole F; Teh BT; Renne G; Minucci S
    J Clin Invest; 2017 Jan; 127(1):153-168. PubMed ID: 27893461
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Benchmarking effects of mTOR, PI3K, and dual PI3K/mTOR inhibitors in hepatocellular and renal cell carcinoma models developing resistance to sunitinib and sorafenib.
    Serova M; de Gramont A; Tijeras-Raballand A; Dos Santos C; Riveiro ME; Slimane K; Faivre S; Raymond E
    Cancer Chemother Pharmacol; 2013 May; 71(5):1297-307. PubMed ID: 23479136
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Co-targeting of Bcl-2 and mTOR pathway triggers synergistic apoptosis in BH3 mimetics resistant acute lymphoblastic leukemia.
    Iacovelli S; Ricciardi MR; Allegretti M; Mirabilii S; Licchetta R; Bergamo P; Rinaldo C; Zeuner A; Foà R; Milella M; McCubrey JA; Martelli AM; Tafuri A
    Oncotarget; 2015 Oct; 6(31):32089-103. PubMed ID: 26392332
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Repurposing of mTOR Complex Inhibitors Attenuates MCL-1 and Sensitizes to PARP Inhibition.
    Mattoo AR; Joun A; Jessup JM
    Mol Cancer Res; 2019 Jan; 17(1):42-53. PubMed ID: 30201826
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MEK inhibition abrogates sunitinib resistance in a renal cell carcinoma patient-derived xenograft model.
    Diaz-Montero CM; Mao FJ; Barnard J; Parker Y; Zamanian-Daryoush M; Pink JJ; Finke JH; Rini BI; Lindner DJ
    Br J Cancer; 2016 Oct; 115(8):920-928. PubMed ID: 27560553
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modulation of Akt/mTOR signaling overcomes sunitinib resistance in renal and prostate cancer cells.
    Makhov PB; Golovine K; Kutikov A; Teper E; Canter DJ; Simhan J; Uzzo RG; Kolenko VM
    Mol Cancer Ther; 2012 Jul; 11(7):1510-7. PubMed ID: 22532600
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ciclopirox olamine inhibits mTORC1 signaling by activation of AMPK.
    Zhou H; Shang C; Wang M; Shen T; Kong L; Yu C; Ye Z; Luo Y; Liu L; Li Y; Huang S
    Biochem Pharmacol; 2016 Sep; 116():39-50. PubMed ID: 27396756
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Platelet-derived growth factor/vascular endothelial growth factor receptor inactivation by sunitinib results in Tsc1/Tsc2-dependent inhibition of TORC1.
    Tran TA; Kinch L; Peña-Llopis S; Kockel L; Grishin N; Jiang H; Brugarolas J
    Mol Cell Biol; 2013 Oct; 33(19):3762-79. PubMed ID: 23878397
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of autophagy enhances sunitinib-induced cytotoxicity in rat pheochromocytoma PC12 cells.
    Ikeda T; Ishii KA; Saito Y; Miura M; Otagiri A; Kawakami Y; Shimano H; Hara H; Takekoshi K
    J Pharmacol Sci; 2013; 121(1):67-73. PubMed ID: 23269235
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of mTOR as a primary resistance factor of the IAP antagonist AT406 in hepatocellular carcinoma cells.
    Zhen MC; Wang FQ; Wu SF; Zhao YL; Liu PG; Yin ZY
    Oncotarget; 2017 Feb; 8(6):9466-9475. PubMed ID: 28036295
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Concurrent inhibition of PI3K and mTORC1/mTORC2 overcomes resistance to rapamycin induced apoptosis by down-regulation of Mcl-1 in mantle cell lymphoma.
    Müller A; Zang C; Chumduri C; Dörken B; Daniel PT; Scholz CW
    Int J Cancer; 2013 Oct; 133(8):1813-24. PubMed ID: 23580240
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Maintaining glycogen synthase kinase-3 activity is critical for mTOR kinase inhibitors to inhibit cancer cell growth.
    Koo J; Yue P; Gal AA; Khuri FR; Sun SY
    Cancer Res; 2014 May; 74(9):2555-68. PubMed ID: 24626091
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular mechanism mediating cytotoxic activity of axitinib in sunitinib-resistant human renal cell carcinoma cells.
    Miyazaki A; Miyake H; Fujisawa M
    Clin Transl Oncol; 2016 Sep; 18(9):893-900. PubMed ID: 26597115
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The antileukemia roles of PP242 alone or in combination with daunorubicin in acute leukemia.
    Shi F; Yang X; Gong Y; Shi R; Yang X; Naren D; Wu J
    Anticancer Drugs; 2015 Apr; 26(4):410-21. PubMed ID: 25535978
    [TBL] [Abstract][Full Text] [Related]  

  • 15. mTOR Complex 2 Stabilizes Mcl-1 Protein by Suppressing Its Glycogen Synthase Kinase 3-Dependent and SCF-FBXW7-Mediated Degradation.
    Koo J; Yue P; Deng X; Khuri FR; Sun SY
    Mol Cell Biol; 2015 Jul; 35(13):2344-55. PubMed ID: 25918246
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Endothelial Cell mTOR Complex-2 Regulates Sprouting Angiogenesis.
    Farhan MA; Carmine-Simmen K; Lewis JD; Moore RB; Murray AG
    PLoS One; 2015; 10(8):e0135245. PubMed ID: 26295809
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Downregulation of mTORC1 and Mcl-1 by lipid-oversupply contributes to islet β-cell apoptosis and dysfunction.
    Li MY; Liu LZ; Xin Q; Zhou J; Zhang X; Zhang R; Wu Z; Yi J; Dong M
    Biochim Biophys Acta Mol Cell Biol Lipids; 2023 Jul; 1868(7):159332. PubMed ID: 37196823
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting the metabolic plasticity of multiple myeloma with FDA-approved ritonavir and metformin.
    Dalva-Aydemir S; Bajpai R; Martinez M; Adekola KU; Kandela I; Wei C; Singhal S; Koblinski JE; Raje NS; Rosen ST; Shanmugam M
    Clin Cancer Res; 2015 Mar; 21(5):1161-71. PubMed ID: 25542900
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic sensitivity to Rac GTPase inhibition requires consequential suppression of mTORC1, AKT, and MEK signaling in breast cancer.
    Hampsch RA; Shee K; Bates D; Lewis LD; Désiré L; Leblond B; Demidenko E; Stefan K; Huang YH; Miller TW
    Oncotarget; 2017 Mar; 8(13):21806-21817. PubMed ID: 28423521
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The dual mTORC1 and mTORC2 inhibitor PP242 shows strong antitumor activity in a pheochromocytoma PC12 cell tumor model.
    Zhang X; Wang X; Qin L; Xu T; Zhu Z; Zhong S; Zhang M; Shen Z
    Urology; 2015 Jan; 85(1):273.e1-7. PubMed ID: 25440763
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.